Protoporphyrin-IX and Manganese Oxide Nanoparticles Encapsulated in Niosomes as Theranostic

10Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Purpose of this study is to develop a multifunctional theranostic agent for both imaging (MR and fluorescence) and combined therapy (photodynamic and radiotherapy). Initially, manganese oxide nanoparticles (MnO NPs) were synthesized and conjugated with diethylenetriaminepentaacetic acid (DTPA) which will be then called as MnO-DTPA NPs, and at the final step, synthesized MnO NPs were encapsulated with niosomes in the presence of protoporphyrin-IX (PP(IX)). In vitro cell culture and bioaffinity studies were performed on PC-3 and BJ cells. The structures (Niosome-MnO-DTPA-PP(IX)) have fluorescence properties and photodynamic therapy potential due to the presence of PP(IX) as well as MR imaging and photodynamic and radiotherapy efficiency. According to data, it was claimed that toxicity of MnO NPs were significantly decreased after encapsulation of niosomes especially for BJ cell line. Therapy potential of the ‘Niosome-MnO-DTPA-PP(IX)’ was examined and promising findings were obtained for the potential use of combined therapy agent for prostate cancer cells.

Cite

CITATION STYLE

APA

Ozada, C., Tekin, V., Barlas, F. B., Timur, S., & Unak, P. (2020). Protoporphyrin-IX and Manganese Oxide Nanoparticles Encapsulated in Niosomes as Theranostic. ChemistrySelect, 5(6), 1987–1993. https://doi.org/10.1002/slct.201901620

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free